Understanding Wegovy Coverage in the United States
Wegovy (semaglutide) has quickly become one of the most prescribed GLP‑1 medications for chronic weight management. Because it is a relatively new, high‑cost therapy, patients often wonder whether their health insurance will cover it and what out‑of‑pocket expenses to expect. This guide breaks down the major U.S. insurers’ formularies, typical cost‑share structures, and practical steps to navigate coverage for Wegovy and related drugs such as Ozempic, Mounjaro, and Zepbound.
Why Insurance Formularies Matter
Insurance companies organize drugs into formularies—lists that rank medications by tier, clinical value, and cost. A drug’s tier determines the patient’s co‑pay or coinsurance. For weight‑loss drugs, many plans place the medication in a higher tier (often Tier 4 or specialty) because of its price and the need for close monitoring. Understanding where Wegovy sits on a plan’s formulary helps patients anticipate their financial responsibility and whether a prior‑authorization (PA) process is required.
Major Commercial Insurers and Wegovy
Below is a snapshot of how the largest commercial carriers currently treat Wegovy in their formularies. Exact tier placement can vary by state, employer group, and plan design, so members should verify details in their own plan documents.
- Aetna: Typically classified as a Tier 4 specialty drug. Requires prior authorization with documented BMI ≥ 30 kg/m² or ≥ 27 kg/m² with a comorbidity. Co‑pay ranges from $150 to $250 per month, depending on the specific plan.
- UnitedHealthcare (UHC): Often listed under the “Weight Management” specialty tier. Prior authorization is mandatory, and UHC may require a trial of other weight‑loss interventions first. Coinsurance is usually 30 % of the drug’s negotiated price, leading to an average monthly cost of $200–$300 for the patient.
- Cigna: Places Wegovy in the “Weight‑Loss Therapy” tier, which is generally Tier 4. A PA is needed, and the plan may limit the number of prescriptions per year. Typical patient cost‑share is a $75 co‑pay plus a 20 % coinsurance, resulting in roughly $150–$250 per month.
- Blue Cross Blue Shield (BCBS) affiliates: Most BCBS plans treat Wegovy as a specialty medication with a prior‑authorization requirement. Co‑pay structures differ widely across the 36 independent BCBS companies, but many members see a $100–$200 co‑pay after meeting their deductible.
Government Programs: Medicare and Medicaid
Because Wegovy is approved for chronic weight management, Medicare Part D plans have begun adding it to their formularies, usually under a specialty tier. Coverage is not universal; some plans still exclude GLP‑1 weight‑loss drugs or place them behind an extensive PA process. Patients on Medicare can expect a 25 % coinsurance after meeting the Part D deductible, which often translates to $150–$300 per month.
Medicaid coverage varies by state. A handful of states have adopted policies that include Wegovy as a covered option for qualifying patients, often with a lower co‑pay than commercial plans but with stricter eligibility criteria (e.g., documented obesity with a related health condition). Because Medicaid formularies are state‑specific, patients should check their local Medicaid agency’s drug list.
Typical Patient Cost‑Share Scenarios
While the exact amount depends on plan design, the following examples illustrate common out‑of‑pocket costs for a 30‑day supply of Wegovy (approximately 1 mg weekly dose):
- Commercial plan with a $150 co‑pay: After meeting the deductible, the patient pays a flat $150 each month, regardless of the drug’s list price.
- Plan with 30 % coinsurance: If the negotiated price is $1,300 per month, the patient’s share is about $390.
- Medicare Part D with 25 % coinsurance: After the deductible (often $445 in 2024), the patient would pay roughly $325 per month.
- State Medicaid program: Some programs cap co‑pays at $25–$50 per month for eligible patients, but they may require additional documentation of obesity‑related comorbidities.
Prior Authorization and the Appeal Process
Because Wegovy is a high‑cost medication, insurers almost universally require a prior authorization. The PA typically asks for:
- Baseline BMI and recent measurements.
- Documentation of at least one obesity‑related comorbidity (e.g., type 2 diabetes, hypertension, sleep apnea).
- Evidence of previous attempts with lifestyle counseling or alternative pharmacotherapy (e.g., metformin, phentermine).
If a PA is denied, most plans allow an appeal. Successful appeals often include:
- Letter of medical necessity from the prescribing clinician.
- Recent lab results or clinical notes that demonstrate the patient’s risk profile.
- Supportive literature highlighting Wegovy’s FDA‑approved indication for chronic weight management.
Tips for Patients to Maximize Coverage
Navigating insurance for weight‑loss drugs can be daunting, but the following strategies can improve the likelihood of approval and reduce out‑of‑pocket costs:
- Know your plan’s tier structure: Review the Summary of Benefits and Coverage (SBC) to see where Wegovy is placed.
- Gather supporting documentation early: Have your provider prepare a concise summary of BMI, comorbidities, and prior weight‑loss attempts.
- Consider “step therapy” compliance: If your insurer requires a trial of another GLP‑1 (e.g., Ozempic) first, discuss the clinical rationale with your doctor.
- Utilize patient assistance programs: Manufacturers often offer coupons or co‑pay assistance for eligible patients, which can dramatically lower monthly costs.
- Stay proactive with renewals: Prior authorizations typically last 12 months. Mark your calendar to request extensions before the expiry date.
Getting Started with GLP‑1
For patients who meet clinical criteria for chronic weight management, the first step is to confirm eligibility through a licensed online provider. These platforms can evaluate BMI, health history, and prior treatment attempts, then issue a prescription if appropriate. To begin the process, you can check your eligibility here. After a prescription is generated, your pharmacy will submit the required prior‑authorization paperwork directly to your insurer, streamlining the path to coverage.
Frequently Asked Questions
Is Wegovy covered the same way as Ozempic?
Both Wegovy and Ozempic contain semaglutide, but they have different FDA indications—Wegovy for chronic weight management and Ozempic for type 2 diabetes. Because of the distinct therapeutic goals, insurers often place them in separate tiers. Ozembic may be covered under a lower‑cost tier for diabetic patients, while Wegovy is usually classified as a specialty weight‑loss drug with higher co‑pays.
Can I use my health savings account (HSA) or flexible spending account (FSA) for Wegovy?
Yes. Since Wegovy is prescribed for a medical condition (obesity), it qualifies as an eligible expense under most HSAs and FSAs. Using these accounts can offset the out‑of‑pocket cost, but the expense must be documented with a prescription and a statement from the insurer indicating the amount paid.
What if my insurance denies coverage for Wegovy?
First, request a written explanation for the denial. Then, work with your prescriber to submit an appeal that includes a medical necessity letter, recent clinical data, and any relevant guidelines (e.g., ADA or AHA recommendations). If the appeal is unsuccessful, explore manufacturer assistance programs or consider alternative GLP‑1 options such as Mounjaro or Zepbound, which may have different coverage criteria.
Do Medicare Advantage plans differ from standard Medicare Part D in covering Wegovy?
Medicare Advantage (MA) plans often bundle prescription drug coverage with medical benefits, and many MA plans have more restrictive formularies than standalone Part D plans. Some MA plans may exclude Wegovy entirely or require higher patient cost‑share. Reviewing the plan’s drug formulary and speaking with a plan representative can clarify coverage specifics.
Medical Disclaimer: This article provides general information and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your healthcare provider and insurance plan documents for personalized guidance regarding Wegovy or any other medication.